Treatment Approach for Pyoderma Gangrenosum

First-Line Treatment Options

Systemic corticosteroids are traditionally considered the first-line treatment for pyoderma gangrenosum, with the therapeutic goal of rapid healing, as recommended by the European Crohn's and Colitis Organisation 1, 2
Topical calcineurin inhibitors, such as tacrolimus or pimecrolimus, can be used as alternatives or adjuncts, particularly for smaller lesions, according to the American Gastroenterological Association 1, 3

Infliximab should be considered if a rapid response to corticosteroids cannot be achieved, with response rates exceeding 90% with short duration pyoderma gangrenosum (<12 weeks) but dropping below 50% for longer-standing cases, as reported by the National Institute for Health and Care Excellence 1, 2, 4
Adalimumab has demonstrated efficacy in case series and can be considered as an alternative anti-TNF option, as suggested by the British Society of Gastroenterology 1, 3

Peristomal pyoderma gangrenosum: Closure of the stoma might lead to resolution of pyoderma gangrenosum lesions in patients with peristomal disease, according to the European Society of Gastrointestinal Endoscopy 1, 5

Initial assessment should include confirmation of diagnosis and identification of any underlying disease, such as inflammatory bowel disease or myeloproliferative disorders, as recommended by the American College of Gastroenterology 2
First-line therapy should begin with systemic corticosteroids, with consideration of topical calcineurin inhibitors for smaller lesions, and implementation of appropriate wound care strategies, as suggested by the Wound Healing Society 1, 2, 3

Misdiagnosis of pyoderma gangrenosum can occur in a substantial percentage of cases, and biopsy from the periphery of the lesion may help exclude other disorders, as reported by the International Society for Stem Cell Research 2, 6
Recurrence risk is high, with pyoderma gangrenosum recurring in more than 25% of cases, often in the same location as the initial episode, according to the European Crohn's and Colitis Organisation 1, 2

The American College of Physicians recommends distinguishing pyoderma gangrenosum from ecthyma gangrenosum, which is a cutaneous vasculitis caused by bacterial invasion, requiring antibiotics, not immunosuppression, with ecthyma gangrenosum presenting as painless erythematous papules progressing to painful necrotic lesions within 24 hours, whereas pyoderma gangrenosum is a sterile inflammatory process 7

The Infectious Diseases Society of America suggests avoiding surgical debridement during active disease, as pathergy (lesion development at trauma sites) is a common feature, and surgical intervention should be reserved for after marrow recovery in neutropenic patients or for progressive necrotizing fasciitis 7